Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM)

Medical Oncology

Volumn 16, Issue 2, 1999, Pages 73-77

  Kyrtsonis, Maria Christina ^a   Mouzaki, Athanasia ^a   Maniatis, Alice ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Hypogammaglobulinaemia; Immunoglobulins; Infections; Multiple myeloma

Indexed keywords

CD23 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA1;

B LYMPHOCYTE; BACTERIAL INFECTION; HUMORAL IMMUNE DEFICIENCY; HYPOGAMMAGLOBULINEMIA; IMMUNE DEFICIENCY; MACROPHAGE; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0032776862     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02785839     Document Type: Review

References (35)

1. Schedel I. Application of immunoglobulin preparations in multiple myeloma. In: Morell A, Nydegger UE (eds). Clinical Use of Intravenous Immunoglobulins. Academic Press: London. 1985, pp 123-132.
2. Sklenar I et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukemia and multiple myeloma. Oncology 1993; 50: 466-477.
3. Hargreaves RM et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 1995; 48: 260-206.
4. Gregersen H et al. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. Eur J Haematol 1998; 61: 140-144.
5. Broder S et al. Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma: Role of suppressor cells. N Engl J Med 1975; 293: 887-892.
6. Kennard J, Zolla-Pazner S. Origin and function of suppressor macrophages in multiple myeloma. J Immunol 1980; 24: 268-273.
7. Farnen JP, Tyrkus M, Hanson CA, Cody RL, Emerson SG. Characterization of a new human multiple myeloma cell line, UMJF-2, which suppresses antibody production by B-lymphocytes in vitro. Leukemia 1991; 5: 574-584.
8. Paglieroni T, Caggiano V, MacKenzie M. Abnormalities in immune regulation precede the development of multiple myeloma. Am J Hematol 1992; 40: 51-55.
9. Carter A, Silivian I, Tatarsky I, Spira G. Impaired immunoglobulin synthesis in multiple myeloma: a B-cell dysfunction. Am J Hematol 1986; 22: 143-154.
10. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regulation 1989; 1: 27-35.
11. Rawstron AC et al. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br J Haematol 1998; 100: 176-183.
12. Tsujimoto T, Lisukov LA, Huang N, Mahmoud MS, Kawano MM. Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. Blood 1996; 97: 3375-3383.
13. Kay NE et al. Circulating blood B cells in multiple myeloma: Analysis of relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the eastern cooperative oncology group phase III E9486 clinical trial. Blood 1997; 90: 340-345.
14. Munshi NC. Immunoregulatory mechanisms in multiple myeloma. Hemat Oncol Clin NA 1997; 11: 51-69.
15. Kawano M et al. Altered cytokine activities are related to the suppression of synthesis of normal immunoglobulin in multiple myeloma. Am J Hematol 1989; 30: 91-96.
16. Kyrtsonis M-C, Dedoussis G, Baxevanis C, Stamatelou M, Maniatis A. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br J Haematol 1996; 92: 420-422.
17. Kyrtsonis M-C et al. Serum transforming growth factor-β1 is related to the degree of immunoparesis in patients with multiple myeloma. Med Oncol 1998; 15: 124-128.
18. Berg DJ, Lynch RG. Immune dysfunction in mice with plasmacytomas. J Immunol 1991; 146: 2865-2872.
19. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J. Growth inhibition by TGF-â linked to suppression of retinoblastoma protein phosphorylation. Cell 1990; 62: 175-185.
20. Ng MHL et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997; 89: 2500-2506.
21. Lapena P et al. Increased production of IL-6 by T lymphocytes from patients with multiple myeloma. Exp Hematol 1996; 24: 26-30.
22. Pilarski LM et al. Abnomal clonogenic potential of T cells from multiple myeloma patients. Blood 1985; 66: 1266-1271.
23. + T cells in peripheral blood of multiple myeloma patients. J Clin Immunol 1988; 8: 259-265.
24. Dianzani U et al. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: Correlation with diagnosis and disease status. Blood 1988; 78: 1064-1073.
25. Massaia M et al. Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 1995; 85: 3679-3687.
26. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998; 9: 3-21.
27. Villunger A et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor induced suppression of immune surveillance. Blood 1997; 90: 12-20.
28. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13: 1-110.
29. Chapel HM, Lee M, Hargreaves R. Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau phase multiple myeloma. Lancet 1994; 343: 1059-1063.
30. Touncouz M, Denys CH, DeGroute D, Dupont E. In vitro inhibition of tumor necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 1995; 89: 698-703.
31. Ruiz de Souza V et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995; 25: 1267-1273.
32. Amran D et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73: 180-186.
33. Hansen MB. Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur J Immunol 1995; 25: 348-354.
34. Oken MM, Pomeroy C, Weisdort D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996; 100: 624-628.
35. Shustik C et al. Glucocorticoid dose related susceptibility to infection in myeloma patients treated with melphalan. Blood 1997; 90: 358a.